A Retrospective Study Comparing Olaparib and Bevacizumab as a Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: Impact on Recurrence-Free Survival in Japanese and Asian Populations

SIMPLE SUMMARY: This study aimed to determine the optimal maintenance therapy and selection criteria for patients with platinum-sensitive recurrent ovarian cancer (PSROC). The study collected retrospective data from 51 patients with PSROC and found that olaparib (Ola) was superior to bevacizumab (Be...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakanishi, Kazuho, Toyoshima, Masafumi, Ueno, Yuta, Suzuki, Shunji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216615/
https://www.ncbi.nlm.nih.gov/pubmed/37345206
http://dx.doi.org/10.3390/cancers15102869

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216615/
https://www.ncbi.nlm.nih.gov/pubmed/37345206
http://dx.doi.org/10.3390/cancers15102869

Ejemplares similares